Chemokine Receptors as Biomarkers in Multiple Sclerosis

Leukocyte infiltrates characterize tissue inflammation and are thought to be integral in the pathogenesis of multiple sclerosis (MS). This attribute underlines the importance of understanding mechanisms of leukocyte migration. Chemokines are secreted proteins which govern leukocyte trafficking into...

Full description

Bibliographic Details
Main Authors:	Fox, Robert J., Kivisäkk, Pia, Lee, Jar-Chi, Tucky, Barbara, Lucchinetti, Claudia, Rudick, Richard A., Ransohoff, Richard M.
Format:	Online
Language:	English
Published:	IOS Press 2006
Online Access:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3850832/

id	pubmed-3850832
recordtype	oai_dc
spelling	pubmed-38508322013-12-18 Chemokine Receptors as Biomarkers in Multiple Sclerosis Fox, Robert J. Kivisäkk, Pia Lee, Jar-Chi Tucky, Barbara Lucchinetti, Claudia Rudick, Richard A. Ransohoff, Richard M. Other Leukocyte infiltrates characterize tissue inflammation and are thought to be integral in the pathogenesis of multiple sclerosis (MS). This attribute underlines the importance of understanding mechanisms of leukocyte migration. Chemokines are secreted proteins which govern leukocyte trafficking into targeted organs. Chemokine receptors (CKR) are differentially expressed on leukocytes and their modulation is a potential target for MS disease modifying therapies. Chemokines and their receptors are also potential biomarkers of both disease activity and response to treatment. We describe the fluctuations in CKR expression on peripheral leukocytes in a group of MS patients followed longitudinally for up to 36 months. We observed little fluctuation in CKR expression within each patient over time, despite considerable variability in CKR expression between patients. These observations suggest that individual patients have a CKR set point, and this set point varies from one patient to another. Evaluation of chemokines or chemokine receptors as biomarkers in MS will need to account for this individual variability in CKR expression. IOS Press 2006 2006-11-15 /pmc/articles/PMC3850832/ /pubmed/17124344 http://dx.doi.org/10.1155/2006/694283 Text en Copyright © 2006 Hindawi Publishing Corporation.
repository_type	Open Access Journal
institution_category	Foreign Institution
institution	US National Center for Biotechnology Information
building	NCBI PubMed
collection	Online Access
language	English
format	Online
author	Fox, Robert J. Kivisäkk, Pia Lee, Jar-Chi Tucky, Barbara Lucchinetti, Claudia Rudick, Richard A. Ransohoff, Richard M.
spellingShingle	Fox, Robert J. Kivisäkk, Pia Lee, Jar-Chi Tucky, Barbara Lucchinetti, Claudia Rudick, Richard A. Ransohoff, Richard M. Chemokine Receptors as Biomarkers in Multiple Sclerosis
author_facet	Fox, Robert J. Kivisäkk, Pia Lee, Jar-Chi Tucky, Barbara Lucchinetti, Claudia Rudick, Richard A. Ransohoff, Richard M.
author_sort	Fox, Robert J.
title	Chemokine Receptors as Biomarkers in Multiple Sclerosis
title_short	Chemokine Receptors as Biomarkers in Multiple Sclerosis
title_full	Chemokine Receptors as Biomarkers in Multiple Sclerosis
title_fullStr	Chemokine Receptors as Biomarkers in Multiple Sclerosis
title_full_unstemmed	Chemokine Receptors as Biomarkers in Multiple Sclerosis
title_sort	chemokine receptors as biomarkers in multiple sclerosis
description	Leukocyte infiltrates characterize tissue inflammation and are thought to be integral in the pathogenesis of multiple sclerosis (MS). This attribute underlines the importance of understanding mechanisms of leukocyte migration. Chemokines are secreted proteins which govern leukocyte trafficking into targeted organs. Chemokine receptors (CKR) are differentially expressed on leukocytes and their modulation is a potential target for MS disease modifying therapies. Chemokines and their receptors are also potential biomarkers of both disease activity and response to treatment. We describe the fluctuations in CKR expression on peripheral leukocytes in a group of MS patients followed longitudinally for up to 36 months. We observed little fluctuation in CKR expression within each patient over time, despite considerable variability in CKR expression between patients. These observations suggest that individual patients have a CKR set point, and this set point varies from one patient to another. Evaluation of chemokines or chemokine receptors as biomarkers in MS will need to account for this individual variability in CKR expression.
publisher	IOS Press
publishDate	2006
url	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3850832/
_version_	1612034365605281792

Chemokine Receptors as Biomarkers in Multiple Sclerosis

Similar Items